Online citations, reference lists, and bibliographies.
← Back to Search

[Anthracycline-induced Cardiomyopathy].

G. Roul, C. Cohen, A. Lieber
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Anthracycline-based antineoplastic therapy is the standard of care for various cancers today and represents a breakthrough in this area. The cardiac toxicity of anthracyclines is well established. The acute form is often reversible and has no predictive value for the future. This early form does not prevent continuation of chemotherapy. Late cardiac toxicity due to anthracycline is the leading limiting factor in its use. In adults, this resembles dilated cardiomyopathy, while in children it may be expressed as restrictive cardiomyopathy. The discovery of modifiable risk factors has made it possible to identify patients at high risk of developing late cardiac toxicity and heart failure. Because left ventricular dysfunction and heart failure may develop long after anthracycline treatment ends, prolonged close follow-up is mandatory in asymptomatic subjects. Follow-up of asymptomatic patients requires serial echocardiography (M-mode, 2D echo, Doppler, tissue Doppler, speckle tracking, etc.). Anthracycline-induced cardiomyopathy must be treated according to the standard guidelines for chronic heart failure with left ventricular dysfunction, by angiotensin-converting enzyme (ACE) inhibitors and beta-blockers. Lifestyle changes may reduce the long-term risk. Close collaboration between cardiologists and oncologists is highly desirable for optimizing management of these patients.



This paper is referenced by
10.1097/MPH.0b013e3181dccd37
Anthracycline-induced Cardiac Toxicity More Likely in Underweight Childhood Cancer Survivors
J. Andolina (2010)
10.1016/S0716-8640(12)70376-0
Estrategias en la prevención de la insuficiencia cardíaca
Vukasovig R. José Luis (2012)
10.1016/J.EJPHAR.2007.11.048
Protective effects of naringenin-7-O-glucoside on doxorubicin-induced apoptosis in H9C2 cells.
X. Han (2008)
10.14503/THIJ-14-4509
Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.
A. Segura (2015)
Doctor of Nursing Practice portfolio of Frederick M. McNeil
F. McNeil (2011)
EVALUATION OF THE POTENTIAL PROTECTIVE EFFECT OF CAPTOPRIL AGAINST DOXORUBICIN-INDUCED CARDIOTOXICITY IN RATS
S. Shouman (2008)
10.7863/jum.2011.30.1.71
Speckle‐Tracking Echocardiography
S. Mondillo (2011)
10.3390/jcdd3040031
Myocarditis in Paediatric Patients: Unveiling the Progression to Dilated Cardiomyopathy and Heart Failure
Inês Teixeira Farinha (2016)
10.3892/mmr.2017.6272
A herbal formula, SYKT, reverses doxorubicin-induced myelosuppression and cardiotoxicity by inhibiting ROS-mediated apoptosis
T. Chen (2017)
10.1152/ajpheart.00172.2015
The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity.
K. Bordun (2015)
10.1179/joc.2010.22.6.402
Overexpression of Vascular Endothelial Growth Factor 165 (VEGF165) Protects Cardiomyocytes Against Doxorubicin-Induced Apoptosis
T. Chen (2010)
10.3390/biology9050098
A Comparative Study of Rat Urine 1H-NMR Metabolome Changes Presumably Arising from Isoproterenol-Induced Heart Necrosis Versus Clarithromycin-Induced QT Interval Prolongation
Matthieu Dallons (2020)
10.1016/j.breast.2020.04.005
Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
N. I. Bouwer (2020)
10.1016/j.ejheart.2007.07.016
Dystrophin‐deficiency increases the susceptibility to doxorubicin‐induced cardiotoxicity
Shiwei Deng (2007)
10.1007/s11010-013-1894-1
Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy
Q. Yu (2013)
10.5114/aoms.2016.59270
Cardiotoxicity of anthracycline therapy: current perspectives
M. Valcovici (2016)
Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats.
M. Iqbal (2008)
10.1080/08880018.2018.1459983
Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors
H. Hu (2018)
10.1155/2013/456409
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
10.1016/j.mito.2013.10.001
Mitochondrial translocator protein (TSPO) ligands prevent doxorubicin-induced mechanical dysfunction and cell death in isolated cardiomyocytes.
A. D. de Tassigny (2013)
10.2147/OTT.S65653
Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients’ heart?
C. Fontanella (2014)
10.1016/j.jacc.2009.03.095
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
D. Cardinale (2010)
10.4061/2011/316927
Cardiac Function in Long-Term Survivors of Childhood Lymphoma
M. Friedberg (2011)
10.1016/j.hrtlng.2012.10.001
Implications for heart failure prevention and treatment of cardiotoxicity in the cancer patient.
C. Lewis (2013)
10.1136/postgradmedj-2015-133535
Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis
Seongseok Yun (2015)
10.1016/j.ijcha.2015.01.002
The role of TNF-α, Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines☆
A. Kouloubinis (2015)
10.2147/IJN.S147464
Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment
C. Pan (2018)
10.1016/j.jchf.2018.08.005
Frequency of Transition From Stage A to Stage B Heart Failure After Initiating Potentially Cardiotoxic Chemotherapy.
Deanna N. Jones (2018)
10.1186/s12967-018-1670-9
An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline
Matteo Sarocchi (2018)
10.3390/jcm9051418
Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
Sonia Gioffré (2020)
10.1345/aph.1K359
Monitoring of Anthracycline-Induced Cardiotoxicity
Abigail Jannazzo (2008)
10.1248/JHS.53.67
Protective Efficacy of Nardostachys jatamansi (Rhizomes) on Mitochondrial Respiration and Lysosomal Hydrolases during Doxorubicin Induced Myocardial Injury in Rats
R. Subashini (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar